<VariationArchive RecordType="classified" VariationID="1451907" VariationName="NC_000015.9:g.(?_42676661)_(42684940_?)del" VariationType="Deletion" Accession="VCV001451907" Version="7" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-11-11" DateCreated="2022-03-28" MostRecentSubmission="2023-11-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1438668" VariationID="1451907">
      <GeneList>
        <Gene Symbol="CAPN3" FullName="calpain 3" GeneID="825" HGNC_ID="HGNC:1480" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q15.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="42359501" stop="42412317" display_start="42359501" display_stop="42412317" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="42651697" stop="42704514" display_start="42651697" display_stop="42704514" Strand="+" />
          </Location>
          <OMIM>114240</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000015.9:g.(?_42676661)_(42684940_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>15q15.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" innerStart="42676661" innerStop="42684940" display_start="42676661" display_stop="42684940" variantLength="8280" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.(?_42676661)_(42684940_?)del" Assembly="GRCh37">
            <Expression>NC_000015.9:g.(?_42676661)_(42684940_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000015.9:g.(?_42676661)_(42684940_?)del AND Autosomal recessive limb-girdle muscular dystrophy type 2A" Accession="RCV002035418" Version="6">
        <ClassifiedConditionList TraitSetID="5780">
          <ClassifiedCondition DB="MedGen" ID="C1869123">Autosomal recessive limb-girdle muscular dystrophy type 2A</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-08-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-08-12" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2023-11-11">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">29797799</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://www.nmd-journal.om/artile/S0960-896608</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="5780" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3064" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Muscular dystrophy, limb-girdle, type 2A, Amish</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Limb-girdle muscular dystrophy, type 2A</ElementValue>
                <XRef ID="Limb-girdle+muscular+dystrophy%2C+type+2A/4236" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Calpainopathy</ElementValue>
                <XRef ID="NBK1313" DB="GeneReviews" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Limb-girdle muscular dystrophy type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Muscular dystrophy, pelvofemoral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leyden-Moebius muscular dystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Autosomal recessive limb-girdle muscular dystrophy type 2A</ElementValue>
                <XRef ID="MONDO:0009675" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">LGMD2</ElementValue>
                <XRef Type="MIM" ID="253600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">LGMDR1</ElementValue>
                <XRef Type="MIM" ID="253600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1057" />
                <XRef ID="1057" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Calpainopathy is characterized by symmetric and progressive weakness of proximal limb-girdle muscles. The age at onset of muscle weakness ranges from two to 40 years. The phenotype shows intra- and interfamilial variability ranging from severe to mild. Three autosomal recessive calpainopathy phenotypes have been identified based on the distribution of muscle weakness and age at onset: Pelvifemoral limb-girdle muscular dystrophy (LGMD) (Leyden-MÃ¶bius LGMD) phenotype, the most frequently observed calpainopathy phenotype, in which muscle weakness is first evident in the pelvic girdle and later in the shoulder girdle, with onset that may occur as early as before age 12 years or as late as after age 30 years. Scapulohumeral LGMD (Erb LGMD) phenotype, usually a milder phenotype with infrequent early onset, in which muscle weakness is first evident in the shoulder girdle and later in the pelvic girdle. HyperCKemia, usually observed in children or young individuals, in which individuals are asymptomatic and have high serum creatine kinase (CK) concentrations. The autosomal dominant form of calpainopathy shows a variability of clinical phenotype, ranging from almost asymptomatic to wheelchair dependence after age 60 years in few cases with a generally milder phenotype than the recessive form. Clinical findings of calpainopathy include the tendency to walk on tiptoe, difficulty in running, scapular winging, waddling gait, and slight hyperlordosis. Other findings include symmetric weakness of proximal more than distal muscles in the limbs, trunk, and periscapular area; laxity of the abdominal muscles; Achilles tendon shortening; scoliosis; and joint contractures. Affected individuals typically do not have cardiac involvement or intellectual disability.</Attribute>
                <XRef ID="NBK1313" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000332444" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000511445" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521018" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000557704" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000560317" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301490</ID>
                <ID Source="BookShelf">NBK1313</ID>
              </Citation>
              <XRef ID="267" DB="Orphanet" />
              <XRef ID="C1869123" DB="MedGen" />
              <XRef ID="MONDO:0009675" DB="MONDO" />
              <XRef Type="MIM" ID="253600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4255054" SubmissionDate="2023-02-03" DateLastUpdated="2023-11-11" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_000070.2_Deletion (Exons 2-7)|MedGen:C1869123" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002234489" DateUpdated="2023-11-11" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29797799</ID>
          </Citation>
          <Citation>
            <URL>https://www.nmd-journal.om/artile/S0960-896608</URL>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 2-7 of the CAPN3 gene. This variant would be expected to be in-frame, preserving the integrity of the reading frame. This variant has not been reported in the literature in individuals affected with CAPN3-related conditions. The region of the CAPN3 gene that includes exon(s) 2-6 has been determined to be clinically significant (PMID: 29797799; https://www.nmd-journal.com/article/S0960-8966(08)00478-1/fulltext). Therefore, deletions that encompass that region are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CAPN3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.(?_42676661)_(42684940_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1869123" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4255054" TraitType="Disease" MappingType="XRef" MappingValue="C1869123" MappingRef="MedGen">
        <MedGen CUI="C1869123" Name="Autosomal recessive limb-girdle muscular dystrophy type 2A" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

